The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis

Shuchong Pan; Laurel S. Kleppe; Tyra A. Witt; Cheryl S. Mueske; Robert D. Simari

doi:10.1160/TH04-01-0006

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(03): 495-502
DOI: 10.1160/TH04-01-0006

Theme Issue Article

Schattauer GmbH

The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis

Authors

Shuchong Pan

¹Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Laurel S. Kleppe

¹Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Tyra A. Witt

¹Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Cheryl S. Mueske

¹Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Robert D. Simari

¹Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Abstract

Summary

Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor that regulates the extrinsic pathway of coagulation by inhibiting the factor VIIa/tissue factor (TF) catalytic complex. TFPI is expressed by both endothelial and smooth muscle cells in the vasculature and circulates at low levels. The role of local vascular TFPI in thrombosis and the development of vascular disease is unknown. To establish an experimental animal model to directly modulate smooth muscle cell-derived TFPI on the development of arterial thrombosis, transgenic mice in which a cDNA encoding murine TFPI is expressed from the murine SM22α promoter were generated. Expression of transgenic mRNA was 4-fold higher than the level of endogenous TFPI mRNA in arteries from transgenic mice. In situ hybridization confirmed that expression of the transgene was limited to medial vascular smooth muscle cells. Vascular TFPI activity was increased to 2 to 3-fold in carotid homogenates. There was no difference in plasma TFPI levels or hemostatic measures (PT, aPTT and tail vein bleeding times) between these mice and their wildtype littermates. In a ferric chloride-induced model of carotid thrombosis, homozygotic transgenic mice demonstrated resistance to thrombotic occlusion compared to wildtype littermates. In transgenic mice 22% occluded within 30 minutes of application while 84% of wild type mice occluded within the same time frame (p <0.01). Heterozygotic transgenic mice had an intermediate thrombotic phenotype. Taken together, these data indicated that local VSMC-specific TFPI overexpression attenuated ferric chloride-induced thrombosis without systemic or hemostatic effects. Furthermore, this transgenic mouse model should prove useful for studying the role of TFPI in the development and progression of vascular disease.

Keywords

Tissue factor / factor VII - tissue factor pathway inhibitor (TFPI) - transgenic animals

Full Text

References

References
1 Broze G, Girard T, Novotny W. Regulation of coagulation by multivalent Kunitz-type inhibitor. Biochem 1990; 29 (33) 7539-46.
2 Hamik A, Setiadi H, Bu G. et al. Downregulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 4962-69.
3 Sevinsky J, Rao L, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133: 293-304.
4 Ott I, Miyagi Y, Miyazaki K. et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arteriolscler Thromb Vasc Biol 2000; 20: 874-82.
5 Bajaj M, Kuppuswamy M, Saito H. et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci, USA 1990; 87: 8869-73.
6 Lindhout T, Blezer R, Schoen P. et al. Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells. Blood 1992; 79: 2909-16.
7 Werling R, Zacharski L, Kisiel W. et al. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
8 van der Logt C, Dirven R, Reitsma P. et al. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis 1994; 05: 211-20.
9 Caplice N, Mueske C, Kleppe L. et al. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-57.
10 Caplice NM, Mueske CS, Kleppe LS. et al. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998; 83: 1264-70.
11 Novotny W, Girard T, Miletich J. et al. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-37.
12 Lesnik P, Vonica A, Guerin M. et al. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993; 13: 1066-75.
13 Hansen J, Huseby K, Sandset P. et al. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-29.
14 Hansen J, Huseby K, Huseby N. et al. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro . Thromb Res 1997; 85: 413-25.
15 Nishida T, Ueno H, Atsuchi N. et al. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit. Circ Res 1999; 84: 1446-52.
16 Golino P, Cirillo P, Calabro’ P. et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001; 38: 569-76.
17 Zoldhelyi P, Chen Z-Q, Shelat H. et al. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA 2001; 98: 4078-83.
18 Atsuchi N, Nishida T, Marutsuka K. et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in ballooninjured rabbit carotid arteries. Circulation 2001; 103: 570-5.
19 Li L, Miano JM, Cserjesi P. et al. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res 1996; 78: 188-95.
20 Solway J, Seltzer J, Samaha FF. et al. Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J Biol Chem 1995; 270: 13460-9.
21 Hogan B, Beddington R, Costantini F. et al. Manipulating the Mouse Embryo: A Laboratory Manual. Second Edition. ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1994
22 Huang ZF, Higuchi D, Lasky N. et al. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-51.
23 Hansen J-B, Huseby K, Huseby N-E. et al. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arteriolscler Thromb Vasc Biol 1995; 15: 879-85.
24 Haskel E, Torr S, Day K. et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein - associated coagulation inhibitor. Circulation 1991; 84: 821-7.
25 Jang Y, Guzman L, Lincoff A. et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-50.
26 Oltrona L, Speidel CM, Recchia D. et al. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipgis. Circulation 1997; 96: 646-52.
27 Zoldhelyi P, McNatt J, Shelat H. et al. Thromboresistance of balloon-injured procine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000; 101: 289-95.
28 Agah R, Prasad K, Linnemann R. et al. Cardiovascular overexpression of transforming growth factor-β₁ causes abnormal yolk sac vasculogenesis and early embryonic death. Circ Res 2000; 86: 1024-30.